A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas

Journal of Neuro-oncology
Priya KumthekarJ J Raizer

Abstract

Standard treatment for GBM is radiation (RT) and temozolomide (TMZ). Arsenic trioxide (ATO) is synergistic with RT based on several mechanisms of action previously identified, however not tested herein. The MTD of ATO, RT and TMZ was determined in a Phase I trial. We now present the combined Phase I/II data. Patients with newly diagnosed malignant gliomas were eligible for treatment. Patients were treated with RT (60 GY), TMZ (75 mg/m2 daily × 42 days) and ATO 0.20 mg/kg daily in week 1 then twice a week ×5 weeks, after completing RT they were treated with TMZ 5/28 for up to 12 months. MRIs were performed every 8 weeks. A total of 42 patients were enrolled in both the Phase I and II trials for this study treatment. Of the 42 enrolled patients (24 M and 18 W) the median age was 54 (24-80) and median KPS 90 (60-100). 28 patients had a GBM and 14 had anaplastic glioma (AG). All patients completed RT/TMZ/ATO and went on to maintenance TMZ. Median number of post RT cycles of TMZ was 4 (0-12). Median PFS was 7 m for GBM and 75 m for AG and median OS was 17 m for GBM and NR for AG. Best response was CR in 2, SD in 28, PR in 5 and PD in 7. There were no unexpected adverse events. Grade 3 toxicities likely attributable to ATO included p...Continue Reading

References

Jul 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D R MacdonaldJ G Cairncross
Sep 1, 2004·International Journal of Radiation Oncology, Biology, Physics·Shoucheng Ning, Susan J Knox
Mar 28, 2006·International Journal of Radiation Oncology, Biology, Physics·Shoucheng Ning, Susan J Knox
May 11, 2010·International Journal of Hematology·Rihab Nasr, Hugues de Thé
Aug 28, 2010·Journal of Hematology & Oncology·Clement YedjouRobert McMurray
Sep 21, 2010·Journal of Neuro-oncology·Aalya FatooJohn A Boockvar
Feb 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Akio IwanamiPaul S Mischel
Apr 30, 2013·Cell Cycle·Akio IwanamiPaul S Mischel
May 23, 2014·The New England Journal of Medicine·Mark R GilbertMinesh P Mehta
May 27, 2014·The New England Journal of Medicine·Olivier L ChinotTimothy Cloughesy
Apr 30, 2015·Journal of Neuro-oncology·Lakshmi NayakAndrew B Lassman
Jul 3, 2016·Neuro-oncology·Wolfgang WickUNKNOWN Neurooncology Working Group (NOA) of the German Cancer Society

❮ Previous
Next ❯

Citations

Mar 22, 2018·Cell Communication and Signaling : CCS·Gabriela Basile CarballoTania Cristina Leite de Sampaio E Spohr
Apr 24, 2020·Scientific Reports·Paulo Henrique Dos Santos KlingerElvis Terci Valera
Sep 29, 2020·Cellular & Molecular Biology Letters·Yi Fang, Zhen Zhang
Jul 28, 2020·Pharmaceuticals·Angel Escamilla-RamírezCristina Trejo-Solís
Sep 10, 2020·Cancers·Md Yousuf AliCorinne E Griguer
Oct 19, 2017·Molecular Cancer Research : MCR·Jonathan B BellLeonidas C Platanias
Jan 28, 2021·Cancers·Alexander OuAmy B Heimberger
Jul 16, 2020·Current Drug Metabolism·Elmira MohtashamiAmir R Afshari
Jul 27, 2021·Medicinal Research Reviews·Marthe SönksenHana Bunzen
Aug 2, 2021·Cellular and Molecular Life Sciences : CMLS·Mariana MedeirosMaría Sol Brassesco

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrophic Gastritis

Atrophic Gastritis is a process where gastric glandular cells are lost and replaced with firbous tissues, as a result of chronic inflammation. Learn more about Atrophic Gastritis here.